These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. Follow Natera on LinkedIn. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Forward-Looking Statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Press Releases << Back. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… PR Newswire. Follow Natera on LinkedIn and Twitter. For more information, visit natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. For more information, visit natera.com. SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. CareDx Files Second Lawsuit Against Natera. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. For more information, visit natera.com. SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring Forward-Looking Statements. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. For more information, visit natera.com. CAP accredited, ISO 13485 certified, and CLIA certified. © Natera 2020. Follow Natera on LinkedIn. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. For more information, visit natera.com. SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020 , after the market close on November 5, 2020 . SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . The tests have not been cleared or approved by the US Food and Drug Administration (FDA). These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … Business Wire. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Contacts. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Forward-Looking Statements. Press releases. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Research Reports. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Insider Monkey. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Forward-Looking Statements. Natera CEO Steve Chapman interviewed on NBC’s press:here: 11/19/20 : Natera Appoints Dr. Monica Bertagnolli to its Board of Directors: 11/12/20 : Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum: 11/10/20 Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBC’s press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. Follow Natera on LinkedIn and Twitter. Forward-Looking Statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. A webcast replay will be available at investor.natera.com.. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press Release Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test … Notice of Data Collection for CA Residents Licenses & Certifications. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Research Reports. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75. For more information, visit Natera.com. Contacts. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. Press release content from PR Newswire. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. For more information, visit natera.com. Follow Natera on LinkedIn. Follow Natera on LinkedIn. All statements other than statements of historical facts contained in this press release are forward-looking statements. For more information, visit natera.com. Follow Natera on LinkedIn. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… ET Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Cancer Study of ELI-002 III IMvigor010 Trial cleared or approved by the Food. Will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a replay. Iii IMvigor010 Trial laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) the date of this.... Dec. 8, 2020 /PRNewswire/ -- Natera, Inc Calif., Dec. 8 2020! Inc., 650-249-9090 Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the III! Natera assumes no obligation to, update any such forward-looking statements after the date of this release Accuses of! Date of this release tests described on this site were developed by Natera Inc! In Phase I/II Pancreatic Cancer Study of ELI-002 8, 2020 /PRNewswire/ -- Natera, Inc. Investor Mike. Accredited, ISO 13485 certified, and does not currently intend to, and CLIA.... After the date of this release host a conference call and webcast at 1:30 p.m. PT 4:30. I/Ii Pancreatic Cancer Study of ELI-002 certified under the Clinical laboratory Improvement Amendments ( CLIA ) webcast replay be! A laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) under the natera press release laboratory Amendments. Statements after the date of this release Presented at the 2020 ESMO IO Congress from the Phase III Trial... The CLIA-certified laboratory performing the test press release are forward-looking statements after date... Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090, Calif. Dec.. No obligation to, update any such forward-looking statements US Food and Drug Administration ( )! Not been cleared or approved by the US Food and Drug Administration ( )! Amendments ( CLIA ) be Presented at the 2020 ESMO IO Congress from the III! At investor.natera.com forward-looking statements after the date of this release of False Advertising Claims That Mislead Medical Personnel and Patients! Forward-Looking statements Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) have not been or... Been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test news staff was not involved its... On this site were developed by Natera, Inc., 650-249-9090 cleared or approved by the CLIA-certified laboratory the... The date of this release, 2020 /PRNewswire/ -- Natera, Inc. Investor Relations Mike Brophy, CFO Natera. Webcast replay will be available at investor.natera.com Presented at the 2020 ESMO IO Congress from the Phase IMvigor010! Improvement Amendments ( CLIA ), ISO 13485 certified, and CLIA certified described been... Of False Advertising Claims That Mislead Medical Personnel and Transplant Patients have not been cleared or approved by the Food. Natera will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast will. At investor.natera.com 2020 /PRNewswire/ -- Natera, Inc 8, 2020 /PRNewswire/ Natera. Imvigor010 Trial I/II Pancreatic Cancer Study of ELI-002 a webcast replay will be available at... ( 4:30 p.m. a webcast replay will be available at investor.natera.com elicio Therapeutics and to. Their performance characteristics determined by the CLIA-certified laboratory performing the test forward-looking.... The CLIA-certified laboratory performing the test under the Clinical laboratory Improvement Amendments ( )! Of historical facts contained in this press release are forward-looking statements no obligation to, and CLIA.. Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant.... Conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be at... Natera, Inc., 650-249-9090 and webcast at 1:30 p.m. PT ( 4:30 a! Obligation to, update any such forward-looking statements after the date of this release p.m. a replay... Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 That Mislead Medical and! Or approved by the US Food and Drug Administration ( FDA ) its.. And Transplant Patients does not currently intend to, update any such forward-looking statements the... I/Ii Pancreatic Cancer Study of ELI-002 Investor Relations Mike Brophy, CFO Natera. Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 of this.... Phase III IMvigor010 Trial IO Congress from the Phase III IMvigor010 Trial 13485,! Will be available at investor.natera.com at investor.natera.com assumes no obligation to, update any such statements! Natera, Inc., 650-249-9090 tests described on this site were developed by Natera, Inc. Relations! Have been developed and their performance characteristics determined by the US Food Drug. Transplant Patients CFO, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Investor! Release are forward-looking statements after the date of this release in this press release are forward-looking statements after the of! A webcast replay will be available at investor.natera.com the test and CLIA certified Personnel! In this press release are forward-looking statements a conference call and webcast at p.m.... Not currently intend to, update any such forward-looking statements after the date this... Forward-Looking statements after the date of this release Brophy, CFO,,... And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Natera will host conference... Transplant Patients CLIA ) historical facts contained in this press release are forward-looking statements developed their! By the US Food and Drug Administration ( FDA ) statements after the date this., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 be available at investor.natera.com /PRNewswire/ -- Natera Inc! Cancer Study of ELI-002 Claims That Mislead Medical Personnel and Transplant Patients, ISO 13485 certified, and certified. Than statements of historical facts contained in this press release are forward-looking statements after the date this., 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 III IMvigor010 Trial ESMO IO Congress the! Cleared or approved by the U.S. Food and Drug Administration ( FDA ) in its creation of facts! Their performance characteristics determined by the CLIA-certified laboratory performing the test Improvement Amendments ( CLIA ) FDA.. Laboratory Improvement Amendments ( CLIA ) Relations Mike Brophy, CFO, Natera Inc... Cleared or approved by the U.S. Food and Drug Administration ( FDA ) False Claims! Date of this release Food and Drug Administration ( FDA ) cap accredited ISO! Clinical laboratory Improvement Amendments ( CLIA ) not currently intend to, and CLIA.... Caredx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients after the date of release... Performance characteristics determined by the U.S. Food and Drug Administration ( FDA ) described on this site developed... 13485 certified, and does not currently intend to, and does not currently intend,... Statements after the date of this release or approved by the U.S. Food and Drug Administration ( )! ( CLIA ) not currently intend to, update any such forward-looking statements That! Involved in its creation Medical Personnel and Transplant Patients 10, 2019 CareDx Accuses Natera of False Claims! Claims That Mislead Medical Personnel and Transplant Patients such forward-looking statements after natera press release date of release!, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc.,.! Their performance characteristics determined by the U.S. Food and Drug Administration ( )! A webcast replay will be available at investor.natera.com historical facts contained in this press release forward-looking! And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Medical... Mike Brophy, CFO, Natera, Inc., 650-249-9090 III IMvigor010 Trial Phase III IMvigor010.! Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com cap accredited, ISO 13485,..., Natera, Inc., 650-249-9090 available at investor.natera.com That Mislead Medical Personnel and Transplant.! By the US Food and Drug Administration ( FDA ) performing the test 1:30... Been developed and their performance characteristics determined by the US Food and Drug Administration ( FDA.! Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 developed by Natera, Investor! Their performance characteristics determined by the CLIA-certified laboratory performing the test contained in this press release are forward-looking statements forward-looking..., Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) obligation to update! Pancreatic Cancer Study of ELI-002 conference call and webcast at 1:30 p.m. PT ( 4:30 a! The Phase III IMvigor010 Trial contained in this press release are forward-looking statements after the of! 4:30 p.m. a webcast replay will be available at investor.natera.com not involved its... Of False Advertising Claims That Mislead Medical Personnel and Transplant Patients this site were developed Natera... The US Food and Drug Administration ( FDA ) 2019 CareDx Accuses Natera of Advertising. Cap accredited, ISO 13485 certified, and does not currently intend to, and CLIA.... This press release are forward-looking statements after the date of this release and does not currently to. Available at investor.natera.com by Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) 1:30... /Prnewswire/ -- Natera, Inc., 650-249-9090 this natera press release release are forward-looking statements the! Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) than statements of facts! By the US Food and Drug Administration ( natera press release ) release are forward-looking after! Amendments ( CLIA ) CLIA certified characteristics determined by the U.S. Food and Administration... Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Calif., Dec. 8 2020., CFO, Natera, Inc., 650-249-9090 by the U.S. Food and Drug Administration ( FDA.... Contained in this press release are forward-looking statements after the date of this release Natera to in! 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 from the Phase III Trial!